Taro Pharmaceuticals U.S.A., Inc. Issues Voluntary Nationwide Recall of Lamotrigine Tablets USP, 100 mg, 100 Count Bottles


Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling one (1) lot of Lamotrigine 100 mg Tablets, Lot # 331771 (expiration date June 2021) in 100 count bottles, NDC 51672-4131-1 to the consumer level. (US Food Recalls) More More

Similar stories

Contaminated Mental Health Drug Recall Adds to Lamictal Risks - DrugWatch.com

Contaminated Mental Health Drug Recall Adds to Lamictal Risks  DrugWatch.com

Posted on 17 April 2020 | 2:00 am | Google News

Recon: Startup EQRx Raises $200M in Effort to Bring Cheaper Drugs to Market; Incyte Buys Rights to MorphoSys CAR-T Rival - Regulatory Focus

Recon: Startup EQRx Raises $200M in Effort to Bring Cheaper Drugs to Market; Incyte Buys Rights to MorphoSys CAR-T Rival  Regulatory Focus

Posted on 13 January 2020 | 3:00 am | Google News

Taro Pharmaceuticals U.S.A., Inc. Issues Voluntary Nationwide Recall of Lamotrigine Tablets USP, 100 mg, 100 Count Bottles - FDA.gov

Taro Pharmaceuticals U.S.A., Inc. Issues Voluntary Nationwide Recall of Lamotrigine Tablets USP, 100 mg, 100 Count Bottles  FDA.gov

Posted on 10 January 2020 | 3:00 am | Google News

Baltimore Week in Review - Baltimore Beat

Baltimore Week in Review  Baltimore Beat

Posted on 15 November 2017 | 3:00 am | Google News

Copyright © 2020 LastMinuteStuff.com | Contact info